Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The time is now

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Jun 08, 2021 9:05am

174 Views

Post# 33346676

RE:The time is now

Exactly! While other development stage pharm beg for funding, ATE has $70M cash in bank. This make the game completely different. We just need to wait for fruits ripening, though slowly.

IrishCanuck wrote: The key to successful investing is capital. Everyone take out second mortgages and max out your credit cards! What's 20% in fees compared to our upside? They can't keep ATE down forever wooooo!!!!!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China